The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

Tempus AI started off the year with a stellar ... a 79% YoY growth, bolstered by the Ambry Genetics acquisition and a rapidly growing TAM. Despite the deep selloff recently, I rank TEM a 'Strong ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

Former House Speaker Nancy Pelosi's stock portfolio has taken a major hit in 2025, aligning with the broader market sell-off.

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit. Northwestern Medicine will be the first system to use Tempus' new algorithm to ...

Tempus AI, a health tech firm, offers AI-powered platforms for treatment decisions, patient care, diagnostics, and molecular profiling, with growing revenue and improving margins. The "AI in ...

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have expanded its clinical footprint to more than 750 sites and 30 million ...